Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Retinoblastoma 1Retinal Neoplasms 1Oropharyngeal Neoplasms 1Nonsquamous Non-small Cell Lung Cancer 1Melanoma 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 10Cisplatin 8Radiotherapy 6Magnetic Resonance Spectroscopy 6Carboplatin 6Specimen Handling 5Paclitaxel 5Brachytherapy 5Fluorodeoxyglucose F18 4dostarlimab 3atezolizumab 3Trastuzumab 3Radiation 3Platinum 3Nivolumab 3Human Papillomavirus DNA Tests 3Docetaxel 3Colposcopy 31,2-diaminocyclohexaneplatinum II citrate 3zimberelimab 2tislelizumab 2spartalizumab 2olaparib 2human papillomavirus vaccine, L1 type 16, 18 2durvalumab 2Vaccines 2Surveys and Questionnaires 2Standard of Care 2Robotic Surgical Procedures 2Radiotherapy, Intensity-Modulated 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Uterine Cervical Neoplasms × Platinum Compounds × Clear all
NCT04906993 2025-09-09

Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Active not recruiting
443 enrolled
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡